Skip to main content
. Author manuscript; available in PMC: 2005 Sep 13.
Published in final edited form as: J Biol Chem. 2004 Jun 21;279(34):35984–35994. doi: 10.1074/jbc.M400408200

Fig. 6. Tsg101 deficiency causes cell death of tumorigenic cells.

Fig. 6

A, experimental design to address whether Tsg101 is dispensable or essential for the survival of neoplastic cells. B, the subcutaneous injection of immortal Tsg101fl/fl 3T3 fibroblasts expressing mutant p53 into whn−/− nude mice (NCr strain) form solid tumors. C, hematoxylin and eosin staining of histological sections from solid tumors (magnification 100×). Note that these lesions are highly vascularized, and tumor cells invade into adjacent normal tissues. V, vasculature; NT, necrotic tumor tissue; MG, mammary gland; M, muscle. D, explanted tumor cells carrying two floxed alleles of Tsg101 (Tsg101fl/fl) infected with pBabe (control) or the pBabe-Cre retroviral vector to excise both copies of Tsg101 (magnification 200×). Note that additional, transforming mutations during neoplastic transformation are incapable of rescuing lethality caused by Tsg101 deficiency. E, MTT color assay to quantify the lack of cell growth of tumor cells lacking Tsg101 compared with their controls. Error bars correspond to S.D.